Your reason for taking a GLP-1 helps determine which tests matter. The evidence on prediabetes concerns a different group from people monitoring established diabetes. Ask your clinician which tests apply to your diagnosis and medicine.
When glucose or kidney monitoring may matter
For diabetes, American Diabetes Association guidance uses A1C or continuous glucose monitoring to assess glucose control [1]. Guidance recommends assessment at least twice a year, with more frequent checks after treatment changes or when goals are unmet. The Wegovy label calls for glucose monitoring before and during treatment in patients with diabetes [2].
The Zepbound label calls for kidney function monitoring when side effects could cause dehydration [3]. Studies on GLP-1 drugs and kidney health cover longer-term outcomes as well. Persistent vomiting or diarrhea should be reported promptly to your clinician.
What researchers proposed for nutrition
A review proposed measuring albumin and total lymphocyte count before treatment and during follow-up [4]. The review’s proposal is separate from the routine monitoring recommended in product labels. A low lymphocyte count alone cannot establish malnutrition.
A post hoc tirzepatide analysis tracked new low lymphocyte counts after treatment began [5]. They occurred in 91 people in the treatment group (n = 3,141) and 28 in the placebo group (n = 1,585). The trials were not designed to test whether these blood tests identify malnutrition. A clinician can assess symptoms, food intake and other possible causes alongside any results.